Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Evolus Inc
(NQ:
EOLS
)
15.86
+0.38 (+2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Evolus Inc
< Previous
1
2
3
4
5
6
Next >
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese
May 09, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus Earnings Preview
May 08, 2023
Via
Benzinga
Evolus to Report First Quarter 2023 Results and Provide Business Update
May 05, 2023
From
Evolus, Inc.
Via
Business Wire
Analyst Expectations for Evolus's Future
March 09, 2023
Via
Benzinga
Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
March 08, 2023
From
Evolus
Via
Business Wire
Preview: Evolus's Earnings
March 07, 2023
Via
Benzinga
Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines
January 30, 2023
Via
Benzinga
Earnings Scheduled For March 8, 2023
March 08, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.
Via
Benzinga
Why Evolus Shares Jumped This Week
January 20, 2023
The company said it expects to turn a profit in the fourth quarter.
Via
The Motley Fool
Evolus to Participate in the Barclays Global Healthcare Conference
February 28, 2023
From
Evolus
Via
Business Wire
Evolus Initiates Nuceiva® Launch in Germany and Austria
February 27, 2023
From
Evolus, Inc.
Via
Business Wire
Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update
February 22, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
February 17, 2023
Via
Benzinga
Evolus Not Affected by Recent Korean Court Ruling
February 10, 2023
From
Evolus
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 07, 2023
Via
Benzinga
Evolus to Participate in the SVB Securities Global Biopharma Conference
January 31, 2023
From
Evolus
Via
Business Wire
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
January 28, 2023
From
Evolus
Via
Business Wire
Evolus Receives Regulatory Approval for Nuceiva® in Australia
January 23, 2023
From
Evolus
Via
Business Wire
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
January 23, 2023
From
Evolus
Via
Business Wire
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
January 19, 2023
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Via
Benzinga
Why Evolus Shares Are Trading Higher Today
January 18, 2023
Evolus, Inc. (NASDAQ: EOLS) shares are trading higher after the company issued fourth-quarter and full-year 2022 and announced full-year 2023 revenue guidance.
Via
Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 18, 2023
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+...
Via
Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
January 18, 2023
From
Evolus
Via
Business Wire
Evolus Extends Term of Credit Facility with Pharmakon Advisors
December 08, 2022
From
Evolus
Via
Business Wire
Evolus Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022
From
Evolus
Via
Business Wire
Evolus to Participate in November Conferences
November 02, 2022
From
Evolus
Via
Business Wire
Evolus to Report Third Quarter 2022 Results and Provide Business Update
October 25, 2022
From
Evolus
Via
Business Wire
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain
October 04, 2022
From
Evolus
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.